Renal effects of angiotensin II receptor blockade in normotensive subjects

Kidney International

Volumn 49, Issue 6, 1996, Pages 1787-1790

  Burnier, Michel ^a   Roch Ramel, Françoise ^a   Brunner, Hans R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN;

BLOOD PRESSURE; CONFERENCE PAPER; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; PRIORITY JOURNAL; SODIUM EXCRETION;

EID: 0029884621     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.268     Document Type: Conference Paper

References (32)

1. WAEBER B, NUSSBERGER J, BRUNNER HR: Angiotensin-converting enzyme inhibitors in hypertension, in Hypertension: Pathophysiology, Diagnosis, and Management, edited by LARAGH JH, BRENNER BM, New York, Raven Press, Ltd, 1990, pp 2209-2232
2. THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429-1435, 1987
3. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
4. KEANE WF, ANDERSON S, AURELL M, DE ZEEUW D, NARINS RG, POVAR G: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Int Med 111:503-516, 1989
5. KON V, FOGO A, ICHIKAWA I, HELLINGS SE, BILLS T: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 44:545-550, 1993
6. TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN WF, BENFIELD P, CARINI DJ, LEE RJ, WEXLER RR, SAYE JAM, SMITH RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205-251, 1993
7. EISKJAER H, SORENSEN SS, DANIELSEN H, PEDERSEN EB: Glomerular and tubular antinatriuretic actions of low-dose angiotensin II infusion in man. J Hypertens 10:1033-1040, 1992
8. HOLLENBERG NK, MEGGS LG, WILLIAMS GH, KATZ J, GARNIC JD, HARRINGTON DP: Sodium intake and renal responses to captopril in normal man and essential hypertension. Kidney Int 20:240-245, 1981
9. MCNABB WR, NOORMOHAMED FH, LANT AF: The effects of enalapril on blood pressure and the kidney in normotensive subjects under altered sodium balance. J Hypertens 4:39-47, 1986
10. LOUTZENHISER R, EPSTEIN M, HAYASHI K, TAKENADA T, FORSTER H: Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: Studies in isolated perfused hydronephrotic kidneys. Am J Hypertens 4:309S-314S, 1991
11. FONTOURA BMA, NUSSENZVEIG DR, TIMMERMANS PBMWM, MAACK T: Dup753 is a potent nonpeptide antagonist of angiotensin II receptors in isolated perfused rat kidney and cultured renal cells. Am J Hypertens 4:303S-308S, 1991
12. FENOY FJ, MILICIC I, SMITH RD, WONG PC, TIMMERMANS PBMWM, ROMAN R: Effects of Dup 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens 4:321S-326S, 1991
13. ZHUO J, THOMAS D, HARRIS PJ, SKINNER SL: The role of endogenous angiotensin II in the regulation of renal haemodynamics and proximal fluid reabsorption in the rat. J Physiol 453:1-13, 1992
14. BOVEE KC, WONG PC, TIMMERMANS PBMWM, THOOLEN MJMC: Effects of nonpeptide angiotensin II receptors antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens 4:327S-333S, 1991
15. BURNIER M, RUTSCHMANN B, NUSSBERGER J, VERSAGGI J, SHAHINFAR S, WAEBER B, BRUNNER HR: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 22:339-347, 1993
16. BURNIER M, PECHÈRE-BERTSCHI A, NUSSBERGER J, WAEBER B, BRUNNER HR: Studies of the renal effects of angiotensin II receptor blockade: The confounding factor of acute water loading on the action of vasoactive systems. Am J Kid Dis 26:108-115, 1995
17. BURNIER M, HAGMAN M, NUSSBERGER J, BIOLLAZ J, ARMAGNAC C, BROUARD R, WAEBER B, BRUNNER HR: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 25:602-609, 1995
18. DOIG JK, MACFADYEN RJ, SWEET CS, LEES KR, REID JL: Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol 21:732-738, 1993
19. MARTINEZ F, SCHMITT F, NATOV S, SAVOIU C, LACOUR B, MADONNA O, GRUNFELD JP, HANNEDOUCHE T: Renal effects of losartan and enalapril alone and in combination in healthy volunteers, in Proceedings of the International Society of Nephrology, Jerusalem, 1993, Gainesville, International Society of Nephrology, 1993, p 228
20. GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Is the antiproteinuric effect of ACE inhibition mediated by interfernece in the renin-angiotensin system? Kidney Int 45:861-867, 1994
21. BURNIER M, WAEBER B, BRUNNER HR: The advantages of angiotensin II antagonism. J Hypertens 12:S7-S15, 1994
22. VOS PF, BOER P, KOOMANS HA: Effects of enalapril on renal sodium handling in healthy subjects on low, intermediate, and high sodium intake. J Cardiovasc Pharmacol 22:27-32, 1993
23. XIE MH, LIU FY, WONG PC, TIMMERMANS PBMWM, COGAN MG: Proximal nephron and renal effects of DuP 753, a nonpeptide angiotensin II receptor antagonist. Kidney Int 38:473-479, 1990
24. NAKASHIMA M, UEMATSU T, KOSUGE K, KANAMURA M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42:333-335, 1992
25. SWEET CS, BRADSTREET DC, BERMAN RS, JALLARD N, SAENZ A, WEIDLER DJ: Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 7:1035-1040, 1994
26. BURNIER M, WAEBER B, BRUNNER HR: Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. J Hypertens 13:S23-S28, 1995
27. ROCH-RAMEL F, GUISAN B: Effect of uricosuric drugs and pyrazinoate on urate uptake by human brush-border membrane vesicles (BBMV). (abstract) Experientia 51:A93, 1995
28. ROCH-RAMEL F, WERNER D, GUISAN B: Urate transport in brush-border membrane of human kidney. Am J Physiol 266:F797-F805, 1994
29. SOFFER BA, WRIGHT JT JR, PRATT JH, WIENS B, GOLDBERG, AI, SWEET CS: Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 26:112-117, 1995
30. MALLION JM, BRADSTREET DC, MAKRIS L, GOLDBERG AI, HALASZ S, SWEET CS, LIM NY, MADONNA O: Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens 13:S35-S41, 1995
31. LAFAYETTE RA, MAYER G, PARK SK, MEYER TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 90:766-771, 1992
32. REMUZZI A, PERICO N, AMUCHASTEGUI CS, MALANCHINI B, MAZERSKA M, BATTAGLIA C, BERTANI T, REMUZZI G: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4:40-49, 1993